Eli Lilly’s Cheaper Insulin Can Fill in for Sanofi’s Lantus (1)

Diabetic patients will now have easier access to insulin after the FDA on Thursday approved Eli Lilly & Co.’s biosimilar as an interchangeable with the biologic drug.

Rezvoglar, which the Food and Drug Administration previously approved in December 2021, can now be swapped out as a substitute for Sanofi’s Lantus at the pharmacy counter without prior authorization from a certified medical prescriber.

Eli Lilly’s drug is the second interchangeable insulin product approved by the FDA—part of the agency’s efforts to offer and ease access to lower-cost treatments for patients.

“This approval furthers FDA’s longstanding commitment to support a competitive ...